14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ATMC vs AFJK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ATMC vs AFJK. Trailing 12-month operating profitability (ATMC 0.0% vs AFJK 0.0%) and valuation multiples (ATMC N/M vs AFJK N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Shell Companies value chain with $37.7M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ATMC vs AFJK Key Questions & Quantitative Answers
As of Nov 20, 2026, AlphaTime Acquisition Corp (ATMC) is the stronger overall head-to-head candidate over Aimei Health Technology Co., Ltd (AFJK) in the Tradestie Institutional Equity Comparison Engine, winning 3–1 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). ATMC carries a Unified Composite Score of 55.0/100 (HOLD) at $15.60 (N/M Forward P/E, 0.0% operating margin), whereas AFJK carries 48.1/100 (HOLD) at $11.78 (N/M Forward P/E, 0.0% operating margin). Technically, ATMC sits in a Neutral phase (RSI N/A, UNCLASSIFIED options structure) and AFJK sits in a Neutral phase (RSI 41.2, UNCLASSIFIED options structure).
AFJK leads the Growth & Scale pillar: ATMC posts +0.0% YoY revenue growth and -46.6% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with AFJK at +0.0% YoY revenue growth and -43.4% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ATMC generates N/A in USD-normalized revenue versus N/A for AFJK. In operating R&D and SG&A reinvestment, ATMC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AFJK.
ATMC and AFJK trade at balanced relative valuation multiples. ATMC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas AFJK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATMC (2.3% ROE) versus AFJK (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, ATMC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, AFJK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.96β · 28% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.